Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
South Puget Sound Neurology
mi
from
Tacoma, WA
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
South Puget Sound Neurology
mi
from
Tacoma, WA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
The Kaufmann Clinic, Inc.
mi
from
Atlanta, GA
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
The Kaufmann Clinic, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Abington Neurological Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc./Simon Williamson Clinic
mi
from
Birmingham, AL
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc./Simon Williamson Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC (Research Site)
mi
from
Chandler, AZ
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC (Research Site)
mi
from
Chandler, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI)
mi
from
Phoenix, AZ
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI)
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc. / Central Phoenix Medical Clinic, LLC
mi
from
Phoenix, AZ
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc. / Central Phoenix Medical Clinic, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona, May Clinic Scottsdale
mi
from
Scottsdale, AZ
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona, May Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
California Advanced Neurotherapeutic, Inc.
mi
from
Los Angeles, CA
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
California Advanced Neurotherapeutic, Inc.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Cedars Sinai Pain Center
mi
from
Los Angeles, CA
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Cedars Sinai Pain Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc./Cassidy Medical Group - Vista
mi
from
Vista, CA
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc./Cassidy Medical Group - Vista
mi
from
Vista, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Georgetown University Hospital
mi
from
Washington,
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Radiant Clinical Research
mi
from
Washington,
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Radiant Clinical Research
mi
from
Washington,
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Broward Research Group
mi
from
Hollywood, FL
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Broward Research Group
mi
from
Hollywood, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
LCC Medical Research Institute, LLC
mi
from
Miami, FL
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
LCC Medical Research Institute, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Well Pharma Medical Research, Corp.
mi
from
Miami, FL
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Well Pharma Medical Research, Corp.
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
QPS MRA, dba Miami Research Associates, LLC
mi
from
South Miami, FL
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
QPS MRA, dba Miami Research Associates, LLC
mi
from
South Miami, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc./Michigan Avenue Internists
mi
from
Chicago, IL
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc./Michigan Avenue Internists
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Norton Neurology Services MS Services
mi
from
Louisville, KY
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Norton Neurology Services MS Services
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
L-MARC Research Center
mi
from
Louisville, KY
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
L-MARC Research Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Seton Medical Group
mi
from
Baltimore, MD
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Seton Medical Group
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Overlea Personal Physicians
mi
from
Baltimore, MD
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Overlea Personal Physicians
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
BTC of New Bedford
mi
from
New Bedford, MA
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
BTC of New Bedford
mi
from
New Bedford, MA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
mi
from
Fremont, NE
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
mi
from
Fremont, NE
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage INC
mi
from
Omaha, NE
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage INC
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Princeton Center for Clinical Research
mi
from
Skillman, NJ
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Princeton Center for Clinical Research
mi
from
Skillman, NJ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Cushing Neuroscience Institute North Shore-LIJ Medical Group
mi
from
Great Neck, NY
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Cushing Neuroscience Institute North Shore-LIJ Medical Group
mi
from
Great Neck, NY
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
ProHealth Care Associates, LLP
mi
from
Plainview, NY
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
ProHealth Care Associates, LLP
mi
from
Plainview, NY
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Volunteer Research Group
mi
from
Knoxville, TN
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Volunteer Research Group
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Baptist Memorial Medical Group (Neurology Specialist - Headache Clinic)
mi
from
Memphis, TN
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Baptist Memorial Medical Group (Neurology Specialist - Headache Clinic)
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Advanced Research Institute
mi
from
Ogden, UT
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Advanced Research Institute
mi
from
Ogden, UT
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
West Virginia University Department of Neurology
mi
from
Morgantown, WV
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
West Virginia University Department of Neurology
mi
from
Morgantown, WV
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin - Department of Neurology
mi
from
Milwaukee, WI
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin - Department of Neurology
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Staccato Prochlorperazine Thorough QT/QTc
Thorough QT/QTc Study of Staccato® Prochlorperazine for Inhalation in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
Covance Clinical Research Unit Inc.
mi
from
Evansville, IN
Staccato Prochlorperazine Thorough QT/QTc
Thorough QT/QTc Study of Staccato® Prochlorperazine for Inhalation in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
Covance Clinical Research Unit Inc.
mi
from
Evansville, IN
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oceanside, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Redlands, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Redlands, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Winter Haven, FL
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Amherst, NY
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Amherst, NY
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Canton, OH
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dayton, OH
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials